About Eyestem
Eyestem is a company based in Bengaluru (India) founded in 2015 by Rajarshi Pal, Jogin Bhairav Desai, Rajani Ravindra Battu, and Dhruv Sareen. Eyestem has raised $19.95 million across 7 funding rounds from investors including Kotak Mahindra Bank, Biological E and Natco Pharma. The company has 1 employees as of March 29, 2024. Eyestem offers products and services including Eyecyte-RPE TM and Eyecyte-PRP TM. Eyestem operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Blue Rock Therapeutics and Gyroscope, among others.
- Headquarter Bengaluru, India
- Employees 1 as on 29 Mar, 2024
- Founders Rajarshi Pal, Jogin Bhairav Desai, Rajani Ravindra Battu, Dhruv Sareen
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eyestem Research Private Limited
- Date of Incorporation 25 Aug, 2015
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$40.09 K (USD)34.43as on Mar 31, 2020
-
Net Profit
-$466.72 K (USD)-102.22as on Mar 31, 2020
-
EBITDA
-$505.45 K (USD)-93.98as on Mar 31, 2020
-
Total Equity Funding
$19.95 M (USD)
in 7 rounds
-
Latest Funding Round
$10 M (USD), Series B
Aug 11, 2025
-
Investors
Kotak Mahindra Bank
& 20 more
-
Employee Count
1
as on Mar 29, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eyestem
Eyestem offers a comprehensive portfolio of products and services, including Eyecyte-RPE TM and Eyecyte-PRP TM.
Treats Dry AMD by restoring retinal pigment epithelium in patients.
Addresses Retinitis Pigmentosa through cell replacement for vision rescue.
Funding Insights of Eyestem
Eyestem has successfully raised a total of $19.95M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eyestem
Eyestem has secured backing from 21 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Kotak Mahindra Bank, Biological E and Natco Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital investing in AI, deep tech, healthcare, and fintech startups.
|
Locked | Locked | Locked | |
|
Bioscience research, innovation, and entrepreneurship facilitation in life sciences are conducted in India.
|
Locked | Locked | Locked | |
|
Seed-stage investments are targeted by Jacesa Investments venture capital firm.
|
Locked | Locked | Locked |
Investor details for Eyestem
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eyestem
Investment portfolio details for Eyestem
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eyestem
Detailed financials for Eyestem
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eyestem Comparisons
Peer comparison for Eyestem
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eyestem
Eyestem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Blue Rock Therapeutics and Gyroscope, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
Detailed competitors of Eyestem
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eyestem
Complete news archive for Eyestem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eyestem
Eyestem was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Eyestem is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Jogin Bhairav Desai is the current CEO of Eyestem. They have also founded this company.
Eyestem is a funded company, having raised a total of $19.95M across 7 funding rounds to date.
As of Mar 29, 2024, the latest employee count at Eyestem is 1.
Annual revenue of Eyestem is $40.09K as on Mar 31, 2020.
Eyestem was founded in 2015 in Bengaluru, India, within the biotechnology sector. Cell replacement therapies targeting ophthalmological conditions, such as dry age-related macular degeneration, are developed. The product Eyecyte-RPE consists of a suspension of retinal pigment epithelium cells derived from human induced pluripotent stem cells. Damaged retinal cells are replaced through this approach, with operations centered on advancing treatments for vision-related disorders in the Indian and global markets.
Eyestem's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Eyestem offers Eyecyte-RPE TM and Eyecyte-PRP TM.
Eyestem has 21 investors. Key investors include Kotak Mahindra Bank, Biological E, Natco Pharma, Alkem Laboratories, and C-CAMP.
The valuation of Eyestem is $42.7M as of Aug 2022.